Tricky, you're welcome. But I actually think the odds are better than a simple count shows. I've gone back to 2013 and the thing is that the drugs that miss the cut seem always to be high risk, with toxicity issues and/or very flawed data sets (e.g. missing chunks of data!). These seem to mostly (not all) get the flick relatively early on. I haven't seen anything scary about Tissue's product - to the contrary in fact its seems very safe.
Of course, there is always a risk with any bio product that it won't go all the way. That's why folks should not invest unless they are prepared to accept that risk.
TIS Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
